Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Portable skin dressing shows promise for rare blistering disease

NCT ID NCT05944250

Symptom relief Sponsor: Stanford University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This pilot study tested a portable device called Spincare that sprays a nanofiber dressing onto wounds in people with recessive dystrophic epidermolysis bullosa (RDEB), a rare genetic condition causing fragile, blistering skin. Six participants with at least six chronic or recurrent wounds were enrolled. The study compared healing of treated wounds versus untreated ones over four months, also tracking side effects like pain or redness. The goal was to see if this easy-to-apply dressing is safe and helps wounds close.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Spincare matrix (a portable device that applies a nanofiber dressing to wounds)
What this could lead to
If it works, this could offer a new, easy-to-use dressing that helps RDEB wounds heal faster and with less pain.
What could go wrong
This is a very small pilot study with only 6 participants, so results may not apply to everyone. The dressing is temporary and not a cure.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

6 people

The number who actually took part.

Started

Sep 2023

Finished

Aug 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

6 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Clinical and/or genetic diagnosis of RDEB by a dermatologist * Age 6 years or older willing and able to give consent/assent * At least 6 wounds (3 wound pairs) each with an area of 10cm2 or greater located at any site (excluding face and genital skin) * Wounds must be present for at least 4 weeks and able to be classified as recurrent wounds (wounds that heal within 12 weeks but then re-blister) vs chronic open (older than 12 weeks) Exclusion Criteria: * Actively infected wounds with pus (colonized wounds are eligible) * Wounds that have had squamous cell carcinoma (SCC) * Wounds on the face and genitals * Wounds that have been treated with investigational therapies in the past 3 months

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Recessive dystrophic epidermolysis bullosa are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

epidermolysis bullosa dystrophica recessive dystrophic epidermolysis bullosa

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Recessive dystrophic epidermolysis bullosa

Contacts and locations

Locations

  • Discovery Hall Stanford University

    Redwood City, California, 94063, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.